| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 05/23/2013 | WO2013074628A1 Controlled release of active using ph |
| 05/23/2013 | WO2013074594A1 Combination therapy of hsp90 inhibitors with braf inhibitors |
| 05/23/2013 | WO2013074583A1 Treatment and prognosis of lymphangioleiomyomatosis |
| 05/23/2013 | WO2013074556A1 Methods of inducing chondrogenesis in mesenchymal stem cells using synthetic triterpenoids |
| 05/23/2013 | WO2013074517A1 Kinase protein binding inhibitors |
| 05/23/2013 | WO2013074459A1 Methods and compositions associated with the granulocyte colony-stimulating factor receptor |
| 05/23/2013 | WO2013074387A1 Imidazole derivatives |
| 05/23/2013 | WO2013074320A1 Alpha-2b receptor agonist and anticonvulsant compositions for treating chronic pain |
| 05/23/2013 | WO2013074205A1 Liquid-filled hard gel capsule pharmaceutical formulations |
| 05/23/2013 | WO2013074059A2 Cytosine deaminase modulators for enhancement of dna transfection |
| 05/23/2013 | WO2013074055A1 Method for restoring and rejuvenating the human body and a pharmaceutical composition for implementation thereof |
| 05/23/2013 | WO2013074049A1 Micronized metformin |
| 05/23/2013 | WO2013074046A1 Pharmaceutical formulations comprising isoflavone |
| 05/23/2013 | WO2013073884A1 Oral complex formulation comprising omega-3 fatty acid and hmg-coa reductase inhibitor with improved stability |
| 05/23/2013 | WO2013073875A1 Novel antiviral pyrrolopyridine derivative and a production method for same |
| 05/23/2013 | WO2013073801A1 Htrpa1-activating composition and use thereof |
| 05/23/2013 | WO2013073763A1 Niacin-peptide having skin whitening activity and use for same |
| 05/23/2013 | WO2013073667A1 Intestinal fibrosis treatment agent |
| 05/23/2013 | WO2013073642A1 Gel of reduced pyrroloquinoline quinone |
| 05/23/2013 | WO2013073620A1 Carotenoid-containing composition and method for producing same |
| 05/23/2013 | WO2013073602A1 Nucleic acid fragment binding to target protein |
| 05/23/2013 | WO2013073577A1 Dihydroxy aromatic heterocyclic compound |
| 05/23/2013 | WO2013073576A1 Nucleic acid molecule for inhibiting activity of rnai molecule |
| 05/23/2013 | WO2013073483A1 Method for producing myo-inositol and myo-inositol derivative |
| 05/23/2013 | WO2013073382A1 Drug for treatment or prevention of nephropathy |
| 05/23/2013 | WO2013073085A1 Apoptosis inducer |
| 05/23/2013 | WO2013072923A1 Process for the preparation of crystalline linezolid |
| 05/23/2013 | WO2013072915A1 Tricyclic compounds, compositions comprising them and uses thereof |
| 05/23/2013 | WO2013072903A1 Nitroimidazoxadiazocine compounds |
| 05/23/2013 | WO2013072902A1 Combination of testosterone and ornithine decarboxylase (odc) inhibitors |
| 05/23/2013 | WO2013072896A1 Structural variants of mycolactones for use in modulating inflammation, immunity and pain |
| 05/23/2013 | WO2013072882A1 2 -amino- 1, 8 -naphthyridine-3 -carboxamide derivatives as antimicrobial agents |
| 05/23/2013 | WO2013072825A1 Phtalazinone derivatives as mpegs -1 inhibitors |
| 05/23/2013 | WO2013072770A2 Pharmaceutical formulations comprising atorvastatin and glimepiride |
| 05/23/2013 | WO2013072767A1 Compositions and preconcentrates comprising at least one salicylate and omega-3 fatty acid oil mixture |
| 05/23/2013 | WO2013072758A1 Pyrimidine diol amides as sodium channel blockers |
| 05/23/2013 | WO2013072745A1 Process for the preparation of tenofovir |
| 05/23/2013 | WO2013072707A1 Treatment of adrenal insufficiency |
| 05/23/2013 | WO2013072705A1 Muscarinic m1 receptor agonists |
| 05/23/2013 | WO2013072703A1 Antibacterial drug derivatives |
| 05/23/2013 | WO2013072694A1 Thieno- and furo - pyrimidines and pyridines, useful as potassium channel inhibitors |
| 05/23/2013 | WO2013072693A1 Thieno [2, 3 - c] pyrazoles for use as potassium channel inhibitors |
| 05/23/2013 | WO2013072676A1 Film-forming formulation |
| 05/23/2013 | WO2013072573A1 Products for oral administration comprising extracts of punica granatum (pomegranate), intended for a pet, and applications of same |
| 05/23/2013 | WO2013072520A1 N-substituted aminobenzocycloheptene, aminotetraline, aminoindane and phenalkylamine derivatives, pharmaceutical compositions containing them, and their use in therapy |
| 05/23/2013 | WO2013072502A1 Pharmaceutically active pyrazine derivatives |
| 05/23/2013 | WO2013072441A1 Composition for protection against cell-damaging effects |
| 05/23/2013 | WO2013072395A1 Tamper-resistant oral pharmaceutical dosage form comprising a pharmacologically active ingredient, an opioid antagonist and/or aversive agent, polyalkylene oxide and anionic polymer |
| 05/23/2013 | WO2013072392A1 Combination of a phosphoinositide 3-kinase inhibitor and a modulator of the janus kinase 2-signal transducer and activator of transcription 5 pathway |
| 05/23/2013 | WO2013072355A1 Mannosylated compounds useful for the prevention and the treatment of infectious diseases |
| 05/23/2013 | WO2013072329A1 Pharmaceutical solid compositions containing ibuprofen salts |
| 05/23/2013 | WO2013072328A1 Use of telaprevir and related compounds in atherosclerosis, heart failure, renal diseases, liver diseases or inflammatory diseases |
| 05/23/2013 | WO2013072327A1 Use of boceprevir and related compounds in atherosclerosis, heart failure, renal diseases, liver diseases or inflammatory diseases |
| 05/23/2013 | WO2013072290A1 Single unit dosage formulations of sevelamer and fat soluble vitamins and surface active agents |
| 05/23/2013 | WO2013072265A1 1-pyridazinyl-hydroxyimino- 3- phenyl- propanes as gpbar1 agonists |
| 05/23/2013 | WO2013072062A1 Composition for transdermal administration of rivastigmine |
| 05/23/2013 | WO2013072050A1 Neramexane mesylate monohydrate and anhydrate |
| 05/23/2013 | WO2013072015A1 Morpholinyl benzotriazine for use in cancer therapy |
| 05/23/2013 | WO2013071880A1 Nitrogen-containing fused ring compounds for use as crth2 antagonists |
| 05/23/2013 | WO2013071865A1 Kinase modulating compounds, compositions containing the same and use thereof |
| 05/23/2013 | WO2013071724A1 Baicalin metal complex and preparation method and application thereof |
| 05/23/2013 | WO2013071698A1 Three-ring pi3k and/or mtor inhibitor |
| 05/23/2013 | WO2013071697A1 Aminoquinazoline derivatives and their salts and methods of use |
| 05/23/2013 | WO2013071696A1 Use of five normal bases in humans for preparation of tumour drugs |
| 05/23/2013 | WO2013071694A1 Oxazole compound and preparation method, pharmaceutical composition and use thereof |
| 05/23/2013 | WO2013071693A1 Oxadiazole compound and preparation method thereof, pharmaceutical composition and use thereof |
| 05/23/2013 | WO2013071456A2 Injectable veterinary composition for sustained release of ceftiofur and florfenicol in animal species, which comprises poly(lacticcoglycolic acid) (plga) microparticles, and the method for the preparation thereof |
| 05/23/2013 | WO2013071421A1 Pharmaceutical composition of amphetamine mixed salts |
| 05/23/2013 | WO2013071418A1 Methods for the synthesis of plasmalogens and plasmalogen derivatives, and therapeutic uses thereof |
| 05/23/2013 | WO2013071415A1 Targeting the rb pathway for the prevention of cancer |
| 05/23/2013 | WO2013071400A1 Apocynin-lipoic acid conjugates and uses thereof cross-reference to related applications |
| 05/23/2013 | WO2013071396A1 Oral leptin formulations and uses thereof |
| 05/23/2013 | WO2013071365A1 A method of treatment and prophylaxis and compositions useful therefor |
| 05/23/2013 | WO2013071353A1 Apricitabine and pi combination therapy |
| 05/23/2013 | WO2013049591A3 Dual inhibitor compounds and methods of use thereof |
| 05/23/2013 | WO2013049531A3 Multilayer magnetic micelle compositions and methods for their use |
| 05/23/2013 | WO2013049382A3 Broad-spectrum antivirals against 3c or 3c-like proteases of picornavirus-like supercluster: picornaviruses, caliciviruses and coronaviruses |
| 05/23/2013 | WO2013049272A3 Composition and method for treatment of symptoms associated with various skin conditions |
| 05/23/2013 | WO2013049026A3 Neurabin scaffolding of the adenosine receptor and rgs4 regulates anti-seizure effect of endogenous adenosine |
| 05/23/2013 | WO2013048989A3 Pyrazole compounds |
| 05/23/2013 | WO2013048214A3 Novel heterocyclic derivatives and their uses |
| 05/23/2013 | WO2013048204A3 Process for preparing paclitaxel from 10-deacetylpaclitaxel |
| 05/23/2013 | WO2013048177A3 Selenophene-fused aromatic compound and manufacturing method thereof |
| 05/23/2013 | WO2013048158A3 Novel usage for eupatilin |
| 05/23/2013 | WO2013042140A3 Non antibiotic,non peptide compounds for antibiotic efficacy & safety enhancement |
| 05/23/2013 | WO2013040535A3 Bicarbocyclic and tricarbocyclic ethynyl derivatives and uses of same |
| 05/23/2013 | WO2013030669A3 Compositions comprising thymoquinone for the treatment of inflammatory diseases |
| 05/23/2013 | WO2013024492A3 A process for the preparation of asenapine and novel salts thereof |
| 05/23/2013 | WO2013021389A3 Downregulation of mir-7 for promotion of beta cell differentiation and insulin production |
| 05/23/2013 | WO2013021260A3 Compounds from anisomeles heyneana |
| 05/23/2013 | WO2013019079A9 Composition containing 5-hydroxyindole compounds or sponge scalarispongia sp. extracts as active ingredients for prevention and treatment of cancer diseases |
| 05/23/2013 | WO2013014314A3 Derivatives of 5-azolone as calpain inhibitors |
| 05/23/2013 | WO2012169785A9 Symmetrically structured quinazoline derivatives |
| 05/23/2013 | WO2012165854A9 Long interfering dsrna simultaneously inducing an immune reaction and the inhibition of the expression of target genes |
| 05/23/2013 | WO2012145575A9 Therapy for leukemia |
| 05/23/2013 | WO2012099285A9 Nano ceramic bone cement using animal bones and preparation method thereof |
| 05/23/2013 | WO2012095793A3 (n-alkylcarbamoyl) methyl enulosides and related pyranoside containing an alfa, beta, gama, delta - unsaturated ester, their preparation and their efficacy as antibacterial agents |
| 05/23/2013 | WO2012089465A3 Use of 13-hydroxy-9,11-octadecadienoic acid for tanning human skin, for dyeing human hair and for treating polymorphous light dermatosis |
| 05/23/2013 | WO2012051318A8 Sulphonamide compounds and methods of making and using same |
| 05/23/2013 | WO2012012443A3 Modulation of dystrophia myotonica-protein kinase (dmpk) expression |